Current ADC treatment trials in both adjuvant (KATHERINE trial) and metastatic settings (DESTINY03 trial) show promise for alternative HER2-positive breast cancer treatment beyond trastuzumab and standard chemotherapy [30, 31]. The gene discussed is ERBB2; the disease is breast cancer.